Comparison of Short- and Long-Term Mortality in Patients with or without Cancer Admitted to the ICU for Septic Shock: A Retrospective Observational Study.

critical care immunocompromised host neoplasms septic shock treatment outcome

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
29 Jun 2022
Historique:
received: 10 06 2022
revised: 27 06 2022
accepted: 28 06 2022
entrez: 9 7 2022
pubmed: 10 7 2022
medline: 10 7 2022
Statut: epublish

Résumé

Introduction: Cancer patients are at high risk of developing septic shock (SSh) and are increasingly admitted to ICU given their improved long-term prognosis. We, therefore, compared the prognosis of cancer and non-cancer patients with SSh. Methods: We conducted a monocentric, retrospective cohort study (2013−2019) on patients admitted to ICU for SSh. We compared the clinical characteristics and management and studied short- and long-term mortality with ICU and in-hospital mortality and 1-year survival according to cancer status. Results: We analyzed 239 ICU stays in 210 patients, 59.5% of whom were men (n = 125), with a median age of 66.5 (IQR 56.3−77.0). Of the 121 cancer patients (57.6% of all patients), 70 had solid tumors (33.3%), and 51 had hematological malignancies (24.3%). When comparing ICU stays of patients with versus without cancer (n = 148 vs. n = 91 stays, respectively), mortality reached 30.4% (n = 45) vs. 30.0% (n = 27) in the ICU (p = 0.95), and 41.6% (n = 59) vs. 35.6% (n = 32) in hospital (p = 0.36), respectively. ICU length of stay (LOS) was 5.0 (2.0−11.3) vs. 6.0 (3.0−15.0) days (p = 0.27), whereas in-hospital LOS was 25.5 (13.8−42.0) vs. 19.5 (10.8−41.0) days (p = 0.33). Upon multivariate analysis, renal replacement therapy (OR = 2.29, CI95%: 1.06−4.93, p = 0.03), disseminated intravascular coagulation (OR = 5.89, CI95%: 2.49−13.92, p < 0.01), and mechanical ventilation (OR = 7.85, CI95%: 2.90−21.20, p < 0.01) were associated with ICU mortality, whereas malignancy, hematological, or solid tumors were not (OR = 1.41, CI95%: 0.65−3.04; p = 0.38). Similarly, overall cancer status was not associated with in-hospital mortality (OR = 1.99, CI95%: 0.98−4.03, p = 0.06); however, solid cancers were associated with increased in-hospital mortality (OR = 2.52, CI95%: 1.12−5.67, p = 0.03). Lastly, mortality was not significantly different at 365-day follow-up between patients with and without cancer. Conclusions: In-hospital and ICU mortality, as well as LOS, were not different in SSh patients with and without cancer, suggesting that malignancies should no longer be considered a barrier to ICU admission.

Identifiants

pubmed: 35804966
pii: cancers14133196
doi: 10.3390/cancers14133196
pmc: PMC9264783
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Crit Care Med. 2012 Jan;40(1):43-9
pubmed: 21926615
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Ann Oncol. 2017 Feb 1;28(2):400-407
pubmed: 27831506
Crit Care Med. 2012 Jan;40(1):55-62
pubmed: 21926606
PLoS One. 2020 Dec 28;15(12):e0243449
pubmed: 33370330
BMJ Open. 2021 Feb 16;11(2):e038349
pubmed: 33593761
Ann Intensive Care. 2011 Mar 23;1(1):5
pubmed: 21906331
Crit Care Med. 2008 Mar;36(3):690-6
pubmed: 18431262
Crit Care Med. 2017 Dec;45(12):2031-2039
pubmed: 28937407
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Support Care Cancer. 2020 Mar;28(3):1325-1333
pubmed: 31243586
Crit Care Med. 2003 Apr;31(4):1250-6
pubmed: 12682500
Support Care Cancer. 2019 Jul;27(7):2413-2424
pubmed: 30993453
Intensive Care Med. 2019 Jul;45(7):977-987
pubmed: 31143998
Crit Care. 2004 Oct;8(5):R291-8
pubmed: 15469571
Curr Opin Crit Care. 2011 Apr;17(2):153-9
pubmed: 21346564
Aust N Z J Public Health. 2020 Feb;44(1):53-58
pubmed: 31535416
Intensive Care Med. 2016 Jun;42(6):1062-4
pubmed: 26858172
Chest. 2006 Jun;129(6):1432-40
pubmed: 16778259
Crit Care Med. 2019 Oct;47(10):1310-1316
pubmed: 31356477
Am J Respir Cell Mol Biol. 2021 Aug;65(2):167-175
pubmed: 33798037
Cancer Immunol Immunother. 2016 Jul;65(7):813-9
pubmed: 26910314
Crit Care Med. 2020 Jun;48(6):822-829
pubmed: 32317596
Crit Care Med. 1981 Aug;9(8):591-7
pubmed: 7261642
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Intensive Care Med. 2017 Sep;43(9):1366-1382
pubmed: 28725926
Cancer Med. 2020 Jun;9(11):3765-3774
pubmed: 32281275
Clin Adv Hematol Oncol. 2012 Dec;10(12):825-6
pubmed: 23271355
Intensive Care Med. 2003 Oct;29(10):1688-95
pubmed: 13680115
Front Med (Lausanne). 2021 Apr 26;8:603275
pubmed: 33981712
Chest. 2014 Nov;146(5):1205-1213
pubmed: 25033349
Oncotarget. 2017 Jan 3;8(1):1860-1870
pubmed: 27661125
J Crit Care. 2012 Jun;27(3):301-7
pubmed: 21855281
Virulence. 2014 Jan 1;5(1):36-44
pubmed: 23774844
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
Cancer Treat Res. 2014;161:43-89
pubmed: 24706221
Crit Care. 2019 May 31;23(1):196
pubmed: 31151462
Ann Am Thorac Soc. 2015 Aug;12(8):1185-92
pubmed: 26086679
Ann Hematol. 2019 May;98(5):1051-1069
pubmed: 30796468
Clin Infect Dis. 2014 Nov 15;59 Suppl 5:S360-4
pubmed: 25352632

Auteurs

Pierrick Le Borgne (P)

Emergency Department, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.
INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), Fédération de Médecine Translationnelle (FMTS), University of Strasbourg, 67000 Strasbourg, France.

Léa Feuillassier (L)

Emergency Department, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.

Maleka Schenck (M)

Service de Médecine Intensive Réanimation, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.

Jean-Etienne Herbrecht (JE)

Service de Médecine Intensive Réanimation, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.

Ralf Janssen-Langenstein (R)

Service de Médecine Intensive Réanimation, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.

Celestine Simand (C)

Institut de Cancérologie Strasbourg Europe, Service d'Hématologie, 67200 Strasbourg, France.

Justine Gantzer (J)

Institut de Cancérologie Strasbourg Europe, Service d'Oncologie Médicale, 67200 Strasbourg, France.

Simon Nannini (S)

Institut de Cancérologie Strasbourg Europe, Service d'Oncologie Médicale, 67200 Strasbourg, France.

Luc-Matthieu Fornecker (LM)

Institut de Cancérologie Strasbourg Europe, Service d'Hématologie, 67200 Strasbourg, France.

Karine Alamé (K)

Emergency Department, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.

François Lefebvre (F)

Department of Public Health, University Hospital of Strasbourg, 67000 Strasbourg, France.

Vincent Castelain (V)

Service de Médecine Intensive Réanimation, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.

Francis Schneider (F)

Service de Médecine Intensive Réanimation, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.

Raphaël Clere-Jehl (R)

Service de Médecine Intensive Réanimation, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.
INSERM (French National Institute of Health and Medical Research), UMR_S1109, Immuno-Rhumatologie Moléculaire, Centre de Recherche d'Immunologie et d'Hématologie, Fédération de Médecine Translationnelle (FMTS), University of Strasbourg, 67000 Strasbourg, France.

Classifications MeSH